Document is current
Any future updates will be listed below
-
Authors
Giorgino, Francesco https://orcid.org/0000-0001-7372-2678
Alzaid, Fawaz https://orcid.org/0000-0003-3056-3640
Pantea Stoian, Anca
Chan, Juliana C. N. https://orcid.org/0000-0003-1325-1194
Ji, Linong https://orcid.org/0000-0002-3262-2168
Lumu, William https://orcid.org/0000-0002-4530-8012
Manrique, Helard https://orcid.org/0000-0002-5064-6147
Mauricio, Didac https://orcid.org/0000-0002-2868-0250
Saboo, Banshi https://orcid.org/0000-0001-7293-8864
Senior, Peter A. https://orcid.org/0000-0003-1033-8673
Yabe, Daisuke https://orcid.org/0000-0002-5334-7687
Zoungas, Sophia https://orcid.org/0000-0003-2672-0949
Meireles, Manuela https://orcid.org/0000-0003-3703-0011
Mathieu, Chantal https://orcid.org/0000-0002-4055-5233
Czupryniak, Leszek https://orcid.org/0000-0003-2396-8885
- License Information
-
More Information
Article History
Received: 14 March 2025
Accepted: 11 June 2025
First Online: 10 September 2025
Acknowledgements
: The EASD Global Council includes the following members: Francesco Giorgino (chair), Fawaz Alzaid, Juliana C. N. Chan, Anca Pantea Stoian, Linong Ji, William Lumu, Didac Mauricio, Helard Manrique, Banshi Saboo, Peter Senior, Daisuke Yabe, Sophia Zoungas, Manuela Meireles and Leszek Czupryniak (advisor).
: This work was supported by the EASD. PAS is supported by the Alberta Academic Medicine Health Services Program and the Charles A. Allard Chair in Diabetes Research.
: FG reports receiving grants from Eli Lilly and Roche Diabetes Care; consulting fees from Eli Lilly and Novo Nordisk and support for attending meetings or for travel from AstraZeneca, Boehringer Ingelheim, Eli Lilly, LifeScan, Merck Sharp & Dohme, Medtronic, Novo Nordisk, Roche Diabetes Care and Sanofi-Aventis. FG has participated on advisory boards for AstraZeneca, Biomea, Boehringer Ingelheim, Eli Lilly, LifeScan, Merck Sharp & Dohme, MedImmune, Medtronic, Novo Nordisk, Roche Diabetes Care and Sanofi-Aventis. FG is Senior Vice-President of the EASD/European Foundation for the Study of Diabetes (EFSD) (unpaid). APS reports participating on advisory boards for Amgen, AstraZeneca, Eli Lilly, Merck, Medtronic, MSD, Novo Nordisk, Roche Diabetes and Sanofi and in the CREDANCE, REIMAGINE 2 and ZEUS research/clinical studies. APS has received fees for meetings, travel or lectures from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Egis, Coca-Cola, Medtronic, Medochemie, Novo Nordisk, Novartis, Merck, MSD, Servier and Sanofi. She is Vice-President of the Romanian Committee of Diabetes, Nutrition, and Metabolic Diseases (unpaid) and Vice-President of Central European Association of Diabetes (CEDA) (unpaid). JCNC reports receiving grants (through institutions) and/or honoraria for consultancy or giving lectures from Abbott, Applied Therapeutics, AstraZeneca, Bayer, Biomea, Boehringer Ingelheim, Eli Lilly, Hua Medicine, Merck, Novo Nordisk, Powder Pharmaceuticals, Roche, Sanofi, Servier and ZP Therapeutics. She is the Chief Executive Officer (pro bono) of the Asia Diabetes Foundation, which developed the web-based JADE platform for implementation of data-driven diabetes care. She is a co-inventor of patents owned by the Chinese University of Hong Kong on biomarkers and models for predicting diabetes and its complications. She is a co-founder of GemVCare, a technology company, with partial support from the Hong Kong Government, which uses biogenetic markers and information technology to implement precision diabetes care and prevention through partnerships. LJ reports receiving consulting or lecture fees from Eli Lilly, Novo Nordisk, Merck, Bayer, Sanofi-Aventis, MSD, AstraZeneca, Boehringer Ingelheim, Abbott, Fosun Pharma, Innovent Biologics, Gan & Lee Pharmaceuticals, Sinocare and Sibionics. HM reports receiving lecture fees from Novo Nordisk. DM has received advisory board and/or speaking fees from AB-Biotics, Abbott, Almirall, Amarna, Amgen, AstraZeneca, Ferrer, Gilead, Lilly, Medtronic, Menarini, MSD, Novo Nordisk and Sanofi. PAS has received speaker and consulting fees from Abbott, Bayer, Dexcom, GSK, Insulet, Novo Nordisk, Vertex and Yposmed. His institution has received grant support from Bayer, the Canadian Institutes of Health Research (CIHR), Brain Canada, Breakthrough T1D and Novo Nordisk. He is a past chair of Diabetes Canada. He serves in leadership roles in Diabetes Action Canada and CanScreen T1D. DY has received clinically commissioned/joint research grants from Novo Nordisk, Ono Pharmaceutical, Taisho Pharmaceutical, Terumo and Arkay. DY has also received consulting or speaker fees from Sumitomo Dainippon Pharma, Boehringer Ingelheim, Astellas Pharma, MSD, Novo Nordisk, Ono Pharmaceutical, Eli Lilly and Takeda Pharmaceuticals. SZ reports previous payments to her institution (Monash University) from AstraZeneca, Boehringer Ingelheim, CSL Seqirus, Eli Lilly Australia, Moderna, MSD Australia, Sanofi and Novo Nordisk for participation in advisory and educational meetings. CM serves or has served on the advisory panel for Novo Nordisk, Sanofi, Eli Lilly, Novartis, Dexcom, Boehringer Ingelheim, Bayer, Roche, Abbott, Medtronic, Insulet, Biomea Fusion, SAB Bio and Vertex. Financial compensation for these activities has been received by KU Leuven. KU Leuven has received research support for CM from Medtronic, Novo Nordisk and Sanofi. CM serves or has served on the speaker’s bureau for Novo Nordisk, Sanofi, Eli Lilly, Medtronic, Dexcom, Insulet, Abbott, Vertex and Boehringer Ingelheim. Financial compensation for these activities has been received by KU Leuven. CM is President of the EASD. All external support for EASD can be found at . The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.
: All authors were responsible for drafting the article and reviewing it critically for important intellectual content. All authors approved the version to be published.
